Biomedical and ICT Convergence Market Outlook and Forecasts 2022 – 2030

Biomedical and ICT Convergence Market Outlook and Forecasts 2022 – 2030

This report evaluates the market for convergence between the Information and Communications Technology (ICT) industry and biomedical science and technologies. The report evaluates the latter and analyzes the former in terms of ICT innovation such as connected medical devices.

In addition to forecasts for IoT connected healthcare devices (standalone, wearable, and implantable), the report also assesses the outlook from 2022 to 2030 for various biomedical products, services, and solutions poised to benefit from various IT and telecom technologies.

Select Report Findings:

The biomedical ICT market is expected to exceed $86 billion USD by 2030

North America will lead the biomedical ICT market during forecasted period

The hardware technology will represent over 50% of the biomedical ICT market

Diagnostic and research will be the prime application area within biomedical ICT market

Biomedical and ICT convergence is the foundation for the preponderance of biomedical tech

The field of biomedicine is concerned with the application of various natural science disciplines for the development of knowledge, interventions, and/or technologies for use in healthcare. The Information and Communications Technology sector focuses on telecommunications, computing, and the integration of both. Related to ICT is the term TMT, which more broadly refers to Technology, Media, and Telecom. Both are related to the use of various digital technologies for communications, applications, commerce, and content. The convergence of biomedical and ICT represents a high opportunity area for both healthcare and ICT industries.

In addition to seeking cures to disease and ailment prevention, the convergence of biomedical and ICT technologies and solutions will lead to improved treatment efficacy as well as overall improvements in healthcare service delivery efficiency and effectiveness. With healthcare costs growing much faster than the general inflation rate, it is of the utmost importance to simultaneously seek improved treatment while continuously driving down business costs. These costs include ongoing operational expenditures as well as expensive R&D such as drug discovery and other pharmaceutical related areas such as vaccine development that takes into account precision medicine practices.

Various ICT tools may be employed such as IoT enabled monitoring to determine the effectiveness of medical procedures, which can be especially important when administering new and unproven healthcare modalities. One specific example is the administration of vaccines, which is believed to potentially cause harm to a subset of the population based on epigenetics, which is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself. This is believed to be an area in which a healthcare modality (in this example, vaccines) is designed with one intent (to inoculate one to prevent the onset of disease), but may actually trigger unintended consequences such as causing harm based on an individual’s unique gene expression.

One of the fastest growing areas for ICT in healthcare is the use of wireless access by IP-enabled, handheld digital devices. Wearables and implantable technology hold the promise of a level of monitoring and healthcare administration that is unprecedented in the history of health science. Ranging from treatment administration to clinical decision support, connected devices are a rapidly evolving tool for the advancement of healthcare practices.

These same tools may be used for both reactive and proactive medical modalities such as insulin modification and vaccine optimization respectively. The convergence of ICT and biomedicine is therefore anticipated to lead to both improved economics (lower costs and improved revenues through identification of new healthcare treatments) as well as improve overall public health.

Companies in Report:

Abbott Laboratories

ActiveLinxx LLC

Agfa Healthcare

Amgen Inc.

Analog Devices

AstraZeneca

Bio Rad Laboratories

Biodirection (NanoDX)

Biogen

BioTelemetry (Philips Company)

Carpenter Technology (CRS Holdings)

Celgene Corporation

Dentsply Sirona

Drager

First Sensor

Fresenius Medical Care

GE Healthcare

Getinge AB

Gilead Sciences

Haier Biomedical

Helmer Scientific

Hoffman-La Roche Ltd.

Honeywell

Jafron Biomedical Co Ltd

Johnson & Johnson Services

KLS Martin Group

Lifesense Group B.V.

Lonza Group

Medtronic

Merck & Co

Nonin Medical

Novartis AG

Novo Nordisk

NXP Semiconductor

Olympus Corporation

Panasonic

Pfizer Inc.

Philips Healthcare

Samsung Healthcare

Sanofi Aventis

Siemens Healthineers

Skanray Technologies

Smiths Medical Inc.

STMicroelectronics

Stryker

TE Connectivity

Texas Instruments

Thermo Fisher

Wright Medical Group

Zimmer Biomet